CMPX revenueQ4 2025$0
- FY YoY
- -100.0%
CMPX revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Compass Therapeutics Inc. (CMPX) financials
For fiscal 2025 (ended Dec 31, 2025), Compass Therapeutics Inc. reported $0 of revenue and -$66.49M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$66.49M
- Free cash flow, FY2025
- -$49.17M
- Cash
- $35.45M
- Market cap
- $137.8M
FY2023FY2025
FY2020FY2025
FY2020FY2025
CMPX revenue and earnings growth
CMPX net incomeQ2 2026-$25.15M
CMPX net income was -$25.15M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$19.88M a year earlier. For the full fiscal 2025 it was -$66.49M, compared with -$49.38M in fiscal 2024.
CMPX free cash flowQ2 2026-$14.91M
CMPX free cash flow was -$14.91M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.83M a year earlier. For the full fiscal 2025 it was -$49.17M, compared with -$44.90M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $850.0K | $0 | - | - | - |
| Research and development | $55.97M | $42.34M | $38.12M | $30.00M | $20.34M | $14.90M |
| Selling, general and admin | $16.87M | $15.13M | $12.24M | $11.66M | $10.93M | $12.91M |
| Operating income | -$72.84M | -$56.63M | -$50.36M | -$41.66M | -$81.88M | -$27.81M |
| Interest expense | - | - | - | $0 | $370.0K | $908.0K |
| Pre-tax income | - | - | -$42.49M | -$39.23M | -$82.18M | -$29.47M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $32.0K |
| Net income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.50M |
| EPS, basic | -$0.42 | -$0.36 | -$0.33 | -$0.37 | -$1.31 | -$0.96 |
| EPS, diluted | - | - | - | - | -$1.31 | -$0.96 |
| Diluted shares | - | 137.4M | - | - | 62.9M | 30.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $30.64M | $43.48M | $24.23M | $34.95M | $144.51M | $47.08M |
| Short-term investments | $178.26M | $83.24M | $128.23M | $151.66M | $0 | - |
| Current assets | $209.82M | $132.75M | $153.88M | $194.79M | $147.10M | $50.20M |
| Total assets | $219.59M | $140.40M | $156.88M | $199.65M | $153.76M | $51.91M |
| Current liabilities | $13.97M | $8.87M | $7.80M | $16.17M | $10.63M | $10.10M |
| Short-term debt | - | - | - | - | $0 | $7.47M |
| Long-term debt | - | - | - | - | $0 | $1.87M |
| Total debt | - | - | - | - | $0 | $9.33M |
| Total liabilities | $22.80M | $15.17M | $8.34M | $18.01M | $13.68M | $11.97M |
| Shareholders' equity | $196.79M | $125.23M | $148.54M | $181.64M | $140.08M | $39.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$49.14M | -$44.85M | -$40.62M | -$34.13M | -$19.67M | -$26.80M |
| Capital expenditures | $25.0K | $44.0K | $30.0K | $212.0K | $1.57M | $106.0K |
| Free cash flow | -$49.17M | -$44.90M | -$40.65M | -$34.34M | -$21.23M | -$26.91M |
| Investing cash flow | -$93.31M | $46.77M | $26.96M | -$151.20M | -$1.77M | $38.0K |
| Financing cash flow | $129.61M | $17.34M | $2.94M | $75.76M | $118.61M | $48.54M |
| Stock-based compensation | $8.37M | $8.56M | $6.12M | $5.33M | $4.03M | $4.02M |
| Depreciation and amortization | $276.0K | $589.0K | $699.0K | $782.0K | $566.0K | $2.40M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | - | - | - | - |
| Operating margin | - | -6661.8% | - | - | - | - |
| Net margin | - | -5808.8% | - | - | - | - |
| Free cash flow margin | - | -5282.2% | - | - | - | - |
| Return on equity | -33.8% | -39.4% | -28.6% | -21.6% | -58.7% | -73.9% |
| Return on assets | -30.3% | -35.2% | -27.1% | -19.6% | -53.4% | -56.8% |
| Current ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 |
| Debt to equity | - | - | - | - | 0.00 | 0.23 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $850.0K | $0 | $0 | $0 |
| Research and development | $19.58M | $13.39M | $13.67M | $12.83M | $16.41M | $13.05M | $13.04M | $8.61M | $11.17M | $9.52M | $12.43M | $8.83M |
| Selling, general and admin | $7.40M | $6.91M | $4.32M | $2.99M | $4.65M | $4.91M | $3.54M | $3.63M | $4.72M | $3.25M | $2.97M | $3.10M |
| Operating income | -$26.98M | -$20.30M | -$17.99M | -$15.82M | -$21.07M | -$17.97M | -$16.57M | -$12.24M | -$15.04M | -$12.77M | -$15.39M | -$11.93M |
| Pre-tax income | - | - | - | - | - | -$16.63M | - | - | -$13.08M | -$10.79M | -$13.41M | -$9.96M |
| Income tax | - | - | - | - | - | $0 | - | - | $0 | $0 | $0 | $0 |
| Net income | -$25.15M | -$18.32M | -$15.72M | -$14.26M | -$19.88M | -$16.63M | -$15.03M | -$10.48M | -$13.08M | -$10.79M | -$13.41M | -$9.96M |
| EPS, basic | -$0.13 | -$0.10 | - | -$0.08 | -$0.14 | -$0.12 | - | -$0.08 | -$0.10 | -$0.08 | - | -$0.08 |
| Diluted shares | - | - | - | - | - | 138.2M | - | 137.6M | - | - | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $35.45M | $55.17M | $30.64M | $46.21M | $22.86M | $41.05M | $43.48M | $19.40M | $19.40M | $43.48M | $24.23M | $30.43M |
| Short-term investments | $144.43M | $139.52M | $178.26M | $173.68M | $78.09M | $71.59M | $83.24M | $98.60M | $126.82M | $132.58M | $128.23M | $133.28M |
| Current assets | $180.89M | $195.69M | $209.82M | $221.12M | $106.19M | $124.14M | $132.75M | $141.14M | $153.55M | $158.61M | $153.88M | $166.58M |
| Total assets | $190.17M | $205.17M | $219.59M | $231.26M | $116.70M | $131.45M | $140.40M | $149.15M | $155.61M | $161.14M | $156.88M | $170.04M |
| Current liabilities | $16.13M | $10.28M | $13.97M | $12.41M | $13.86M | $14.90M | $8.87M | $4.43M | $9.51M | $3.89M | $7.80M | $9.12M |
| Total liabilities | $24.12M | $18.70M | $22.80M | $21.65M | $23.49M | $21.17M | $15.17M | $10.75M | $9.51M | $4.08M | $8.34M | $9.99M |
| Shareholders' equity | $166.05M | $186.47M | $196.79M | $209.61M | $93.21M | $110.28M | $125.23M | $138.40M | $146.10M | $157.06M | $148.54M | $160.04M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.74M | -$17.27M | -$13.25M | -$10.85M | -$11.83M | -$13.21M | -$9.16M | -$11.05M | -$10.75M | -$13.89M | -$12.35M | -$5.92M |
| Capital expenditures | $176.0K | $82.0K | $0 | $7.0K | $0 | $18.0K | $0 | $44.0K | $0 | $0 | $9.0K | $10.0K |
| Free cash flow | -$14.91M | -$17.35M | -$13.25M | -$10.86M | -$11.83M | -$13.23M | -$9.16M | -$11.10M | -$10.75M | -$13.89M | -$12.36M | -$5.93M |
| Investing cash flow | -$4.98M | $38.43M | -$3.38M | -$95.16M | -$6.36M | $11.59M | $15.37M | $29.02M | $6.48M | -$4.10M | $6.31M | $17.05M |
| Financing cash flow | $0 | $3.37M | $1.06M | $129.36M | $0 | -$815.0K | -$94.0K | -$2.0K | $1.0K | $17.43M | -$158.0K | $21.0K |
| Stock-based compensation | $4.82M | $5.07M | $1.82M | $1.24M | $2.79M | $2.51M | $2.24M | $2.20M | $2.12M | $2.00M | $1.60M | $1.63M |
| Depreciation and amortization | $21.0K | $15.0K | $17.0K | $19.0K | $100.0K | $140.0K | $140.0K | $143.0K | $152.0K | $154.0K | $161.0K | $164.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | -1770.0% | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | -1538.4% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -1265.2% | - | - | - |
| Current ratio | 11.22 | 19.04 | 15.02 | 17.82 | 7.66 | 8.33 | 14.96 | 31.84 | 16.15 | 40.74 | 19.73 | 18.26 |
Source: XBRL data Compass Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CMPX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CMPX | $0 | -100.0% | -$66.49M | - | $137.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.23B | -27.6% | -$3.15B | -141.4% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
CMPX FAQ
7 questionsWhat is CMPX revenue?
Compass Therapeutics Inc. (CMPX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is CMPX profitable?
No. Compass Therapeutics Inc. reported a net loss of $66.49M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does CMPX have?
Compass Therapeutics Inc. reported $35.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CMPX revenue growing?
Compass Therapeutics Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is CMPX free cash flow?
Compass Therapeutics Inc. generated -$49.17M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$49.14M less capital expenditures.When did CMPX last report financial results?
The latest statements here come from Compass Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this CMPX financial data come from?
Quantisnow builds these statements from the structured XBRL data Compass Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.